Springer publishes anthology with the Nanoet... ( Springer and The Nanoethics Group ha...)

Springer publishes anthology with the Nanoethics Group

Date:4/28/2008

Springer and The Nanoethics Group have released a collection of important papers addressing a range of near-term issues related to nanotechnologys ethical and social implications. The anthology Nanotechnology and Society: Current and Emerging Ethical Issues tackles such contentious issues as environmental impact, health dangers, medical benefits, intellectual property, professional code of ethics, privacy, international governance, and more.

The anthology features sixteen papers focused on the most urgent issues arising from nanotechnology today and in the near future. Written by leading researchers, policy experts, and nanoethics scholars worldwide, the book is divided into five units: foundational issues; risk and regulation; industry and policy; the human condition; and selected global issues.

While there are also more distant and speculative issues in nanoethicsand weve touched upon some of them in our previous workit is important to also have a single volume focused on the more immediate problems facing nanotechnology, especially as policymakers and industry are interested in these issues first and foremost, said Patrick Lin, Ph.D., director for The Nanoethics Group.

The volume is co-edited by Fritz Allhoff (Western Michigan Univ.) and Patrick Lin (Cal Poly, SLO; Dartmouth College) and presents papers by notable names in nanotechnology and nanoethics, including (in order of appearance): Jean-Pierre Dupuy (Stanford), Paul Thompson (Michigan State Univ.), Arthur Zucker (Ohio Univ.), David Berube (North Carolina State Univ.), Thomas Powers (Univ. of Delaware), Ashley Shew (Virginia Tech), Jeroen van den Hoven (Delft Univ. of Tech., Netherlands), Drew Harris (Graves Dougherty Hearon & Moody), Raj Bawa (Bawa Biotechnology Consulting LLP), Summer Johnson (Albany Medical College), Jason Robert (Arizona State Univ.), and Joachim Schummer (Tech. Univ. of Darmstadt, Germany). Organizations such as Canadas Commission de l'thique de la
'/>"/>

Contact: Joan Robinson
joan.robinson@springer.com
49-622-148-78130
Springer
Source:Eurekalert

0

GOOD

Page: 1 2
Related biology technology :

1. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. The Lancet Publishes Vasogens ACCLAIM Results
4. Consortium publishes Phase II map of human genetic variation
5. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
6. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
7. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
8. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
9. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
10. Sloning and the Kornberg group at Stanford University starting evaluation project regarding the synthesis of a Statistically Randomized Gene Library
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group

Post Your Comments:

(Date:11/6/2009)...LLEY, Calif., Nov. 6 Calbiotech, I...ll Business Innovative Research (SBIR) Phase I con...al command. Under terms of the agreement, Calbiote...or the diagnosis of Dengue virus. ,, Dengue ...s a major threat to military forces deployed to tr...

(Date:11/5/2009)...URG, Md., Nov. 5 GenVec,...al results for the third quarter ended September 3...n ($0.04 per share) for the three months ended Sep...lion ($0.08 per share) in the comparable quarter o...09, GenVec,s net loss was $14.1 million ($0.15 per...

(Date:11/5/2009)...e Call on Thursday, November 5, 2009 at 4:30 p.m. ... 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceutic... OGXI ) today reported unaudited financial results...mber 30, 2009 and reviewed the Company,s highlight...ng consolidated results reflect the operations of ...

(Date:11/5/2009)..., CA, November 5, 2009 S...n using proprietary taste receptor-based technolog...ood, beverage, and ingredient supply industries, t...ncial results for the third quarter ended Septembe...ird quarter of 2009, compared to $4.0 million for ...

[0] Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus [0] GenVec Reports Third Quarter 2009 Financial Results [0] OncoGenex Reports Third Quarter 2009 Financial Results [0] SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS

...raTag(TM) technology,s ability to ...ANCISCO, Calif., May 16 Monogram,Biosciences, Inc...,collaborators will present results on HERmark(TM)...o measure HER2 and predict response to,Herceptin(R... cancer at the,upcoming 44th ASCO Annual Meeting t...

...r Aqua Bounty to scale back commitment to i... TSX symbol: SBS, CALGARY, May 1...,(TSX:SBS), a biotechnology company developing a p... cardiovascular diseases, today announced that,its... shrimp feed additive,program, Aqua Bounty Technol...

...oration,announced today that it has enrolled and r... IIb trial with oral larazotide acetate, an inhibi...atment of patients with active,celiac disease (CD)...d,placebo-controlled study will evaluate the clini...lity of larazotide acetate in 106 active CD,subjec...

Other Biology Technology:Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 2 Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 3 Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 4 Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting 5 SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 2 SemBioSys provides update on shrimp feed additive, Immunosphere(TM) 3 Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 2 Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease 3

Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting SemBioSys provides update on shrimp feed additive, Immunosphere(TM)Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease

(Date:11/4/2009)...r 4, 2009 Childhood obesity in the United States ...ne fourth of advertising on daytime and prime time...tinuing questions about the role television plays ... of the Journal of Nutrition Education and Behavi...n might be a large contributor to the problem. , ...

(Date:11/4/2009)...ry that deciphered the DNA codes, or genomes, of t...has joined The Genome 10K Project, an internationa...sequences on 10,000 species of animals for conduct...can not be achieved. , Participating in The Geno...the Nov. 5, 2009 issue of the Journal of Heredity...

(Date:11/4/2009)...lif., Oct. 19 Spectros, developer ... imaging devices which shed light on life-threaten...xclusive distribution deals for both its T-Stat...covered include Australia, New Zealand, The Nethe...taly, France, Spain, Portugal, Poland, Greece, Tur...

Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2 TV bombards children with commercials for high-fat and high-sugar foods 3 Singapore scientists join international study of 10,000 vertebrates' genomes 2 Spectros Signs New International Distribution Deals 2 TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 1 TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 2 TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 3 TFAH Applauds Affordable Health Choices Act for Making Prevention a Cornerstone of Health Reform 48518 4 Organogenesis Launches Regenerative Medicine College Scholarship 48514 1 Organogenesis Launches Regenerative Medicine College Scholarship 48514 2 Organogenesis Launches Regenerative Medicine College Scholarship 48514 3 Gene Can Dampen Chemo Drug Effectiveness 48510 1

[0] TV bombards children with commercials for high-fat and high-sugar foods [0] Singapore scientists join international study of 10,000 vertebrates' genomes [0] Spectros Signs New International Distribution Deals

...king part in protein folding to ensure cells funct...g molecular motions provides researchers with info...hem decipher the bases of certain diseases, such a...lecular motion gone awry. , In the past, researche...clusters to run simulations. Or they had to be con...

...that a direct interaction between vitamin D and a ...ng multiple sclerosis (MS). The research, publishe...enetics , suggests that vitamin D deficiency durin...isk of the offspring developing MS later in life. ...ndition affecting young adults. More than 85,000 p...

...YSE: CSC ) announced today that it is one of 12 ...pport Services Unrestricted contract by the Depart...(BTF). The indefinite-delivery/indefinite-quantity... solutions and task orders to meet the mission nee... has a three-year base period and two one-year opt...

Other Biology News:New open-source software permits faster desktop computer simulations of molecular motion 2 New open-source software permits faster desktop computer simulations of molecular motion 3 Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 2 Genetic study shows direct link between vitamin D and MS susceptibility 'gene' 3 CSC Awarded Department of Defense Biometrics Contract 2

New open-source software permits faster desktop computer simulations of molecular motion Genetic study shows direct link between vitamin D and MS susceptibility 'gene'CSC Awarded Department of Defense Biometrics Contract

Cassette, Hind III from Takara Mirus Bio

Cassette, EcoR I from Takara Mirus Bio

EcoR I Adaptors from Promega

Cassette, Sal I from Takara Mirus Bio

Biology Products:

Cassette, Hind III from Takara Mirus Bio Cassette, EcoR I from Takara Mirus Bio EcoR I Adaptors from Promega Cassette, Sal I from Takara Mirus Bio

Springer publishes anthology with the Nanoet...( Springer and The Nanoethics Group ha...)